BEIGF
BeOne Medicines AG
Price Chart
Latest Quote
$22.50
+0.00 (+0.00%)
Current Price
| Previous Close | $22.50 |
| Open | $23.75 |
| Day High | $23.75 |
| Day Low | $23.75 |
| Volume | 100 |
Stock Information
| Shares Outstanding | 1.23B |
| Total Debt | $1.15B |
| Cash Equivalents | $4.79B |
| Revenue | $5.74B |
| Net Income | $513.02M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $30.35B |
| P/E Ratio | 66.19 |
| EPS (TTM) | $0.34 |
| Exchange | PNK |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $28.88B |
| Sales | $5.74B |
| Income | $513.02M |
| Book/sh | $3.30 |
| Cash/sh | $3.88 |
| Employees | 12K |
Financial Ratios
| Quick Ratio | 3.17 |
| Current Ratio | 3.64 |
| Debt/Eq | 24.14 |
| EPS Growth TTM | 17802.10% |
Returns & Margins
| ROA | 5.96% |
| ROE | 12.42% |
| Gross Margin | 88.31% |
| Operating Margin | 16.51% |
| Profit Margin | 8.94% |
Ownership
| Insider Ownership | 13.87% |
| Institutional Ownership | 28.11% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| P/S | 5.29 |
| P/B | 6.83 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $22.50 |
| SMA50 | $22.75 |
| SMA200 | $21.91 |
| RSI | nan |
| ATR | 0.0890 |
| Shares Float | 1.01B |
| Volatility | 0.50 |
| Rel Volume | 20.00 |
Performance History
| Week | +0.00% |
| Month | +0.00% |
| Quarter | -5.25% |
| 6 Months | -11.03% |
| YTD | -11.03% |
| Year | +41.09% |
| 10 Years | +34.11% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-04 | $22.50 | 100 |
| 2026-06-03 | $22.50 | 0 |
| 2026-06-02 | $22.50 | 0 |
| 2026-06-01 | $22.50 | 0 |
| 2026-05-29 | $22.50 | 0 |
| 2026-05-28 | $22.50 | 0 |
| 2026-05-27 | $22.50 | 0 |
| 2026-05-26 | $22.50 | 0 |
| 2026-05-22 | $22.50 | 0 |
| 2026-05-21 | $22.50 | 0 |
| 2026-05-20 | $22.50 | 0 |
| 2026-05-19 | $22.50 | 0 |
| 2026-05-18 | $22.50 | 0 |
| 2026-05-15 | $22.50 | 0 |
| 2026-05-14 | $22.50 | 0 |
| 2026-05-13 | $22.50 | 0 |
| 2026-05-12 | $22.50 | 0 |
| 2026-05-11 | $22.50 | 0 |
| 2026-05-08 | $22.50 | 0 |
| 2026-05-07 | $22.50 | 0 |
| 2026-05-06 | $22.50 | 0 |
| 2026-05-05 | $22.50 | 0 |
About BeOne Medicines AG
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK targeting chimeric degradation activation compound active against wild type and mutant BTK; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187 and BG-C0902, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC. It also has various preclinical programs. The company has agreements Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. The company was formerly known as BeiGene, Ltd. and changed its name to BeOne Medicines AG in May 2025. BeOne Medicines AG was founded in 2010 and is based in Basel, Switzerland.
đ° Latest News
BeOne Medicines Signals Solid Tumor Breakout as Three Programs Near Phase 3
MarketBeat âĸ 2026-06-02T06:09:17Z
How The BeOne Medicines (ONC) Story Is Shifting With Sonrotoclax And Brukinsa
Simply Wall St. âĸ 2026-05-23T22:11:25Z
Leerink Raises its Price Target on BeOne Medicines (ONC)
Insider Monkey âĸ 2026-05-22T10:59:40Z
Guggenheim Lifts BeOne Medicines (ONC) Price Target, Keeps Buy Rating
Insider Monkey âĸ 2026-05-14T20:00:26Z
Morgan Stanley Maintains an âOverweightâ Rating on BeOne Medicines AG (ONC)
Insider Monkey âĸ 2026-05-13T17:55:20Z
BeOne Medicines' (NASDAQ:ONC) Performance Is Even Better Than Its Earnings Suggest
Simply Wall St. âĸ 2026-05-13T11:35:32Z
Earnings Beat: BeOne Medicines AG Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Simply Wall St. âĸ 2026-05-08T13:23:28Z
BeOne Medicines Q1 Earnings Call Highlights
MarketBeat âĸ 2026-05-06T20:42:49Z
Did FDA Fast-Track HER2 Regimen Just Shift BeOne Medicines' (ONC) Investment Narrative?
Simply Wall St. âĸ 2026-05-05T09:08:54Z
AMD downgraded, Airbnb upgraded: Wall Street's top analyst calls
The Fly âĸ 2026-05-04T13:43:08Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $594,089,000 | $379,920,000 | $286,475,000 | $119,199,000 |
| Cost Of Revenue | $594,089,000 | $379,920,000 | $286,475,000 | $164,906,000 |
| Total Revenue | $3,810,241,000 | $2,458,779,000 | $1,415,921,000 | $1,176,283,000 |
| Operating Revenue | $4,786,744,000 | $2,974,857,000 | $1,590,256,000 | $1,291,120,000 |
| Expenses | ||||
| Total Expenses | $4,378,440,000 | $3,666,515,000 | $3,205,586,000 | $2,615,018,000 |
| Other Income Expense | $-12,638,000 | $307,891,000 | $-223,852,000 | $15,904,000 |
| Other Non Operating Income Expenses | $-12,638,000 | $307,891,000 | $-223,852,000 | $15,904,000 |
| Net Non Operating Interest Income Expense | $47,836,000 | $74,009,000 | $52,480,000 | $-15,757,000 |
| Operating Expense | $3,784,351,000 | $3,286,595,000 | $2,919,111,000 | $2,450,112,000 |
| Total Other Finance Cost | - | $-74,009,000 | $-52,480,000 | $15,757,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-644,786,000 | $-881,708,000 | $-2,003,815,000 | $-1,457,816,000 |
| Net Interest Income | $47,836,000 | $74,009,000 | $52,480,000 | $-15,757,000 |
| Interest Income | $47,836,000 | $74,009,000 | $52,480,000 | - |
| Normalized Income | $-644,786,000 | $-881,708,000 | $-2,003,815,000 | $-1,457,816,000 |
| Net Income From Continuing And Discontinued Operation | $-644,786,000 | $-881,708,000 | $-2,003,815,000 | $-1,457,816,000 |
| Total Operating Income As Reported | $-568,199,000 | $-1,207,736,000 | $-1,789,665,000 | $-1,438,735,000 |
| Net Income Common Stockholders | $-644,786,000 | $-881,708,000 | $-2,003,815,000 | $-1,457,816,000 |
| Net Income | $-644,786,000 | $-881,708,000 | $-2,003,815,000 | $-1,457,816,000 |
| Net Income Including Noncontrolling Interests | $-644,786,000 | $-881,708,000 | $-2,003,815,000 | $-1,457,816,000 |
| Net Income Continuous Operations | $-644,786,000 | $-881,708,000 | $-2,003,815,000 | $-1,457,816,000 |
| Pretax Income | $-533,001,000 | $-825,836,000 | $-1,961,037,000 | $-1,438,588,000 |
| Interest Income Non Operating | $47,836,000 | $74,009,000 | $52,480,000 | - |
| Operating Income | $-568,199,000 | $-1,207,736,000 | $-1,789,665,000 | $-1,438,735,000 |
| Gross Profit | $3,216,152,000 | $2,078,859,000 | $1,129,446,000 | $1,011,377,000 |
| Depreciation Amortization Depletion Income Statement | - | $3,500,000 | $751,000 | $750,000 |
| Depreciation And Amortization In Income Statement | - | $3,500,000 | $751,000 | $750,000 |
| Amortization Of Intangibles Income Statement | - | $3,500,000 | $751,000 | $750,000 |
| Per Share | ||||
| Diluted EPS | $-0.47 | $-0.65 | $-1.49 | $-1.17 |
| Basic EPS | $-0.47 | $-0.65 | $-1.49 | $-1.17 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-396,437,000 | $-1,120,061,000 | $-1,723,387,000 | $-1,392,278,000 |
| Reconciled Depreciation | $171,762,000 | $87,675,000 | $66,278,000 | $46,457,000 |
| EBITDA (Bullshit earnings) | $-396,437,000 | $-1,120,061,000 | $-1,723,387,000 | $-1,392,278,000 |
| EBIT | $-568,199,000 | $-1,207,736,000 | $-1,789,665,000 | $-1,438,735,000 |
| Diluted Average Shares | $1,368,746,793 | $1,357,034,547 | $1,340,729,572 | $1,206,210,049 |
| Basic Average Shares | $1,368,746,793 | $1,357,034,547 | $1,340,729,572 | $1,206,210,049 |
| Diluted NI Availto Com Stockholders | $-644,786,000 | $-881,708,000 | $-2,003,815,000 | $-1,457,816,000 |
| Tax Provision | $111,785,000 | $55,872,000 | $42,778,000 | $19,228,000 |
| Research And Development | $1,953,295,000 | $1,778,594,000 | $1,640,508,000 | $1,459,239,000 |
| Selling General And Administration | $1,831,056,000 | $1,508,001,000 | $1,278,603,000 | $990,123,000 |
| Amortization | - | $3,500,000 | $751,000 | $750,000 |
| Minority Interests | - | - | $0 | $0 |
Fetched: 2026-02-02
Balance Sheet (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $3,202,457,000 | $3,428,472,000 | $4,288,787,000 | $6,029,106,000 |
| Total Assets | $5,920,910,000 | $5,805,275,000 | $6,379,290,000 | $8,535,525,000 |
| Total Non Current Assets | $1,929,317,000 | $1,601,861,000 | $1,172,212,000 | $921,645,000 |
| Other Non Current Assets | $10,506,000 | $10,906,000 | $12,440,000 | $13,490,000 |
| Non Current Prepaid Assets | $15,124,000 | $20,668,000 | $49,446,000 | $41,399,000 |
| Goodwill And Other Intangible Assets | $129,765,000 | $108,855,000 | $94,568,000 | $103,457,000 |
| Other Intangible Assets | $129,765,000 | $108,855,000 | $94,568,000 | $103,348,000 |
| Current Assets | $3,991,593,000 | $4,203,414,000 | $5,207,078,000 | $7,613,880,000 |
| Other Current Assets | $15,882,000 | $44,780,000 | - | - |
| Restricted Cash | $9,312,000 | $11,473,000 | $196,000 | $328,000 |
| Prepaid Assets | $134,897,000 | $163,353,000 | $190,737,000 | $253,111,000 |
| Inventory | $494,986,000 | $416,122,000 | $282,346,000 | $242,626,000 |
| Receivables | $709,106,000 | $395,886,000 | $198,984,000 | $500,175,000 |
| Other Receivables | $32,828,000 | $37,859,000 | $22,777,000 | $12,010,000 |
| Accounts Receivable | $676,278,000 | $358,027,000 | $173,168,000 | $483,113,000 |
| Cash Cash Equivalents And Short Term Investments | $2,627,410,000 | $3,171,800,000 | $4,534,815,000 | $6,617,640,000 |
| Cash And Cash Equivalents | $2,627,410,000 | $3,171,800,000 | $3,869,564,000 | $4,375,678,000 |
| Accrued Interest Receivable | - | $1,735,000 | $3,039,000 | $5,052,000 |
| Allowance For Doubtful Accounts Receivable | - | - | $-211,000 | $-415,000 |
| Gross Accounts Receivable | - | - | $173,379,000 | $483,528,000 |
| Non Current Deferred Assets | - | - | - | $110,424,000 |
| Non Current Deferred Taxes Assets | - | - | - | $110,424,000 |
| Debt | ||||
| Total Debt | $1,079,866,000 | $930,185,000 | $596,675,000 | $694,644,000 |
| Long Term Debt And Capital Lease Obligation | $210,761,000 | $219,869,000 | $243,665,000 | $245,154,000 |
| Long Term Debt | $166,484,000 | $197,618,000 | $209,148,000 | $202,113,000 |
| Current Debt And Capital Lease Obligation | $869,105,000 | $710,316,000 | $353,010,000 | $449,490,000 |
| Current Debt | $851,529,000 | $688,366,000 | $328,969,000 | $427,565,000 |
| Other Current Borrowings | $89,383,000 | $112,974,000 | $128,969,000 | $227,565,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $2,588,688,000 | $2,267,948,000 | $1,995,935,000 | $2,402,962,000 |
| Total Non Current Liabilities Net Minority Interest | $373,789,000 | $457,835,000 | $527,407,000 | $803,407,000 |
| Other Non Current Liabilities | $70,498,000 | $171,146,000 | $179,784,000 | $269,629,000 |
| Non Current Deferred Liabilities | $72,331,000 | $50,698,000 | $96,198,000 | $280,810,000 |
| Non Current Deferred Taxes Liabilities | $42,007,000 | $16,494,000 | $15,996,000 | $14,169,000 |
| Current Liabilities | $2,214,899,000 | $1,810,113,000 | $1,468,528,000 | $1,599,555,000 |
| Other Current Liabilities | $111,154,000 | $68,004,000 | $114,335,000 | $120,801,000 |
| Payables And Accrued Expenses | $986,292,000 | $813,990,000 | $602,547,000 | $701,884,000 |
| Payables | $487,787,000 | $387,310,000 | $369,756,000 | $356,763,000 |
| Other Payable | $21,956,000 | $19,165,000 | $30,971,000 | $27,307,000 |
| Total Tax Payable | $60,834,000 | $53,034,000 | $44,004,000 | $67,056,000 |
| Accounts Payable | $404,997,000 | $315,111,000 | $294,781,000 | $262,400,000 |
| Current Deferred Liabilities | - | $0 | $213,861,000 | $187,414,000 |
| Equity | ||||
| Common Stock Equity | $3,332,222,000 | $3,537,327,000 | $4,383,355,000 | $6,132,563,000 |
| Total Equity Gross Minority Interest | $3,332,222,000 | $3,537,327,000 | $4,383,355,000 | $6,132,563,000 |
| Stockholders Equity | $3,332,222,000 | $3,537,327,000 | $4,383,355,000 | $6,132,563,000 |
| Gains Losses Not Affecting Retained Earnings | $-148,988,000 | $-99,446,000 | $-77,417,000 | $17,950,000 |
| Other Equity Adjustments | $-148,988,000 | $-99,446,000 | $-77,417,000 | $17,950,000 |
| Retained Earnings | $-8,606,836,000 | $-7,962,050,000 | $-7,080,342,000 | $-5,076,527,000 |
| Other | ||||
| Ordinary Shares Number | $1,384,840,687 | $1,354,719,193 | $1,356,140,180 | $1,334,804,281 |
| Share Issued | $1,384,840,687 | $1,354,719,193 | $1,356,140,180 | $1,334,804,281 |
| Tangible Book Value | $3,202,457,000 | $3,428,472,000 | $4,288,787,000 | $6,029,106,000 |
| Invested Capital | $4,350,235,000 | $4,423,311,000 | $4,921,472,000 | $6,762,241,000 |
| Working Capital | $1,776,694,000 | $2,393,301,000 | $3,738,550,000 | $6,014,325,000 |
| Capital Lease Obligations | $61,853,000 | $44,201,000 | $58,558,000 | $64,966,000 |
| Total Capitalization | $3,498,706,000 | $3,734,945,000 | $4,592,503,000 | $6,334,676,000 |
| Additional Paid In Capital | $12,087,908,000 | $11,598,688,000 | $11,540,979,000 | $11,191,007,000 |
| Capital Stock | $138,000 | $135,000 | $135,000 | $133,000 |
| Common Stock | $138,000 | $135,000 | $135,000 | $133,000 |
| Employee Benefits | $16,405,000 | $14,995,000 | $7,760,000 | $7,814,000 |
| Non Current Pension And Other Postretirement Benefit Plans | $16,405,000 | $14,995,000 | $7,760,000 | $7,814,000 |
| Non Current Deferred Revenue | $30,324,000 | $34,204,000 | $80,202,000 | $266,641,000 |
| Long Term Capital Lease Obligation | $44,277,000 | $22,251,000 | $34,517,000 | $43,041,000 |
| Long Term Provisions | $3,794,000 | $1,127,000 | - | - |
| Current Capital Lease Obligation | $17,576,000 | $21,950,000 | $24,041,000 | $21,925,000 |
| Line Of Credit | $762,146,000 | $575,392,000 | $200,000,000 | $200,000,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $248,348,000 | $217,803,000 | $184,775,000 | $139,966,000 |
| Current Accrued Expenses | $498,505,000 | $426,680,000 | $232,791,000 | $345,121,000 |
| Investments And Advances | $128,933,000 | $89,644,000 | $91,779,000 | $100,792,000 |
| Net PPE | $1,644,989,000 | $1,371,788,000 | $923,979,000 | $662,507,000 |
| Accumulated Depreciation | $-399,105,000 | $-249,212,000 | $-171,470,000 | $-124,286,000 |
| Gross PPE | $2,044,094,000 | $1,621,000,000 | $1,095,449,000 | $786,793,000 |
| Leases | $64,680,000 | $60,124,000 | $53,786,000 | $50,288,000 |
| Construction In Progress | $659,945,000 | $744,759,000 | $315,652,000 | $200,983,000 |
| Other Properties | $545,779,000 | $435,695,000 | $390,595,000 | $298,550,000 |
| Machinery Furniture Equipment | $100,348,000 | $83,281,000 | $47,483,000 | $27,404,000 |
| Buildings And Improvements | $607,857,000 | $231,656,000 | $222,448,000 | $144,083,000 |
| Land And Improvements | $65,485,000 | $65,485,000 | $65,485,000 | $65,485,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $264,284,000 | $228,252,000 | $172,503,000 | $155,089,000 |
| Work In Process | $60,118,000 | $39,098,000 | $20,886,000 | $9,397,000 |
| Raw Materials | $170,584,000 | $148,772,000 | $88,957,000 | $78,140,000 |
| Current Deferred Revenue | - | $0 | $213,861,000 | $187,414,000 |
| Other Short Term Investments | - | $2,600,000 | $665,251,000 | $2,241,962,000 |
| Goodwill | - | - | $109,000 | $109,000 |
Fetched: 2026-02-02
Cash Flow Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-669,768,000 | $-1,753,714,000 | $-1,965,718,000 | $-1,613,574,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-140,631,000 | $-1,157,453,000 | $-1,496,619,000 | $-1,298,723,000 |
| Cash Flow From Continuing Operating Activities | $-140,631,000 | $-1,157,453,000 | $-1,496,619,000 | $-1,298,723,000 |
| Operating Gains Losses | - | - | $21,996,000 | $-7,632,000 |
| Investing Activities | ||||
| Capital Expenditure | $-529,137,000 | $-596,261,000 | $-469,099,000 | $-314,851,000 |
| Investing Cash Flow | $-548,350,000 | $60,004,000 | $1,077,123,000 | $640,659,000 |
| Cash Flow From Continuing Investing Activities | $-548,350,000 | $60,004,000 | $1,077,123,000 | $640,659,000 |
| Net Other Investing Changes | $-2,862,000 | $-2,075,000 | $-1,485,000 | - |
| Financing Activities | ||||
| Financing Cash Flow | $193,449,000 | $416,478,000 | $-18,971,000 | $3,636,911,000 |
| Cash Flow From Continuing Financing Activities | $193,449,000 | $416,478,000 | $-18,971,000 | $3,636,911,000 |
| Net Other Financing Charges | $3,000,000 | - | - | - |
| Issuance Of Capital Stock | - | $0 | $0 | $3,442,616,000 |
| Net Common Stock Issuance | - | $0 | $0 | $3,442,616,000 |
| Common Stock Issuance | - | $0 | $0 | $3,442,616,000 |
| Other | ||||
| Repayment Of Debt | $-732,247,000 | $-323,266,000 | $-417,081,000 | $-321,754,000 |
| Issuance Of Debt | $877,323,000 | $684,032,000 | $351,146,000 | $423,287,000 |
| Interest Paid Supplemental Data | $51,175,000 | $19,753,000 | $25,169,000 | $29,967,000 |
| Income Tax Paid Supplemental Data | $69,430,000 | $56,003,000 | $29,500,000 | $15,695,000 |
| End Cash Position | $2,638,747,000 | $3,185,984,000 | $3,875,037,000 | $4,382,887,000 |
| Beginning Cash Position | $3,185,984,000 | $3,875,037,000 | $4,382,887,000 | $1,390,005,000 |
| Effect Of Exchange Rate Changes | $-51,705,000 | $-8,082,000 | $-69,383,000 | $14,035,000 |
| Changes In Cash | $-495,532,000 | $-680,971,000 | $-438,467,000 | $2,978,847,000 |
| Proceeds From Stock Option Exercised | $45,373,000 | $55,712,000 | $46,964,000 | $92,762,000 |
| Net Issuance Payments Of Debt | $145,076,000 | $360,766,000 | $-65,935,000 | $101,533,000 |
| Net Short Term Debt Issuance | $164,054,000 | $351,954,000 | $-103,307,000 | $84,695,000 |
| Short Term Debt Payments | $-704,216,000 | $-309,576,000 | $-417,081,000 | $-321,754,000 |
| Short Term Debt Issuance | $868,270,000 | $661,530,000 | $313,774,000 | $406,449,000 |
| Net Long Term Debt Issuance | $-18,978,000 | $8,812,000 | $37,372,000 | $16,838,000 |
| Long Term Debt Payments | $-28,031,000 | $-13,690,000 | $0 | $0 |
| Long Term Debt Issuance | $9,053,000 | $22,502,000 | $37,372,000 | $16,838,000 |
| Net Investment Purchase And Sale | $-16,351,000 | $658,340,000 | $1,547,707,000 | $955,510,000 |
| Sale Of Investment | $2,655,000 | $673,240,000 | $1,563,618,000 | $3,146,891,000 |
| Purchase Of Investment | $-19,006,000 | $-14,900,000 | $-15,911,000 | $-2,191,381,000 |
| Net Intangibles Purchase And Sale | $-36,474,000 | $-34,365,000 | $-143,665,000 | $-51,909,000 |
| Purchase Of Intangibles | $-36,474,000 | $-34,365,000 | $-143,665,000 | $-51,909,000 |
| Net PPE Purchase And Sale | $-492,663,000 | $-561,896,000 | $-325,434,000 | $-262,942,000 |
| Purchase Of PPE | $-492,663,000 | $-561,896,000 | $-325,434,000 | $-262,942,000 |
| Change In Working Capital | $-157,167,000 | $-370,539,000 | $132,391,000 | $-118,345,000 |
| Change In Other Working Capital | $633,000 | $-255,587,000 | $-151,816,000 | $407,703,000 |
| Change In Other Current Liabilities | $-14,838,000 | $587,000 | $-1,209,000 | $-2,620,000 |
| Change In Other Current Assets | $45,126,000 | $12,120,000 | $-3,282,000 | $-107,128,000 |
| Change In Payables And Accrued Expense | $232,851,000 | $201,595,000 | $41,275,000 | $160,052,000 |
| Change In Accrued Expense | $111,354,000 | $180,111,000 | $45,627,000 | $140,044,000 |
| Change In Payable | $121,497,000 | $21,484,000 | $-4,352,000 | $20,008,000 |
| Change In Account Payable | $121,497,000 | $21,484,000 | $-4,352,000 | $20,008,000 |
| Change In Inventory | $-91,496,000 | $-140,948,000 | $-56,689,000 | $-153,333,000 |
| Change In Receivables | $-329,443,000 | $-188,306,000 | $304,112,000 | $-423,019,000 |
| Changes In Account Receivables | $-329,443,000 | $-188,306,000 | $304,112,000 | $-423,019,000 |
| Other Non Cash Items | $-2,063,000 | $-377,409,000 | $-18,690,000 | $-5,476,000 |
| Stock Based Compensation | $441,618,000 | $367,618,000 | $303,162,000 | $240,712,000 |
| Unrealized Gain Loss On Investment Securities | $24,022,000 | $16,221,000 | $21,996,000 | $-7,632,000 |
| Deferred Tax | $25,983,000 | $689,000 | $2,059,000 | $3,377,000 |
| Deferred Income Tax | $25,983,000 | $689,000 | $2,059,000 | $3,377,000 |
| Depreciation Amortization Depletion | $171,762,000 | $87,675,000 | $66,278,000 | $46,457,000 |
| Depreciation And Amortization | $171,762,000 | $87,675,000 | $66,278,000 | $46,457,000 |
| Amortization Cash Flow | $4,824,000 | $7,239,000 | $3,976,000 | $1,715,000 |
| Amortization Of Intangibles | $4,824,000 | $7,239,000 | $3,976,000 | $1,715,000 |
| Depreciation | $166,938,000 | $80,436,000 | $62,302,000 | $44,742,000 |
| Net Income From Continuing Operations | $-644,786,000 | $-881,708,000 | $-2,003,815,000 | $-1,457,816,000 |
| Earnings Losses From Equity Investments | - | - | $21,996,000 | $-7,632,000 |
Fetched: 2026-02-02